Overview
Tirzepatide is a 39-amino acid dual incretin receptor agonist that activates both GLP-1 and GIP receptors, supporting glycemic control and weight management through enhanced insulin secretion and appetite suppression.
Key Characteristics
– Half-life: Approximately 5 days
– Administration: Once-weekly subcutaneous injection
– Concentration: 10.0 mg/mL (when reconstituted with 3.0 mL bacteriostatic water)
– Typical dosage range: 2.5–15 mg weekly
Reconstitution Instructions
1. Draw 3.0 mL bacteriostatic water with sterile syringe
2. Inject slowly down vial wall to avoid foaming
3. Gently swirl/roll until dissolved (do not shake)
4. Label with reconstitution date
5. Storage: Refrigerate at 2–8 °C (35.6–46.4 °F), protected from light
6. Shelf life: Use within 28 days of reconstitution
Standard Dosage Protocol
| Phase | Weekly Dose | Units (U-100 Syringe) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 25 units (0.25 mL) |
| Weeks 5–8 | 5 mg | 50 units (0.50 mL) |
| Weeks 9–12 | 7.5 mg | 75 units (0.75 mL) |
| Weeks 13–16 | 10 mg | 100 units (1.0 mL) |
Note: Dose increases occur every 4 weeks to minimize gastrointestinal effects. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated.
Injection Technique
– Clean vial stopper and injection site with alcohol; allow to dry
– Pinch skinfold; insert needle at 45–90° angle into subcutaneous tissue
– Do not aspirate for subcutaneous injections
– Inject slowly and steadily
– Rotate sites systematically (abdomen, thighs, upper arms)
– Dispose of needles in sharps container immediately
Storage Guidelines
Lyophilized vials: Store at −20 °C (−4 °F) in dry, dark conditions
Reconstituted solution: Refrigerate at 2–8 °C; do not freeze
Duration: Use within 28 days of reconstitution
Supplies Needed (per protocol duration)
– Insulin syringes (U-100, 1 mL): One per week
– Bacteriostatic water: 3.0 mL per vial
– Alcohol swabs: Two per injection day
– Sharps container: For safe needle disposal
Mechanism of Action
Tirzepatide simultaneously activates GLP-1 and GIP receptors, which:
– Enhance glucose-dependent insulin secretion
– Suppress glucagon release
– Slow gastric emptying
– Promote satiety through central appetite regulation
– The dual GIP activity appears to synergistically amplify effects beyond GLP-1 agonists alone
Potential Benefits
– Significant HbA1c reductions in type 2 diabetes
– Substantial body-weight loss (up to ~11 kg more than GLP-1 comparators over 26 weeks at higher doses)
– Improvements in lipid profiles and blood pressure
Common Side Effects
– Gastrointestinal: Nausea, diarrhea, vomiting, constipation (typically mild-to-moderate and dose-dependent)
– Injection-site reactions: Occasional mild redness or irritation
– Gradual titration reduces incidence of adverse effects
Lifestyle Recommendations
– Pair with balanced, calorie-appropriate diet; reduced appetite may naturally decrease intake
– Prioritize protein to preserve lean mass during weight loss
– Combine resistance training and aerobic activity
– Maintain hydration, especially with potential gastrointestinal effects
– Prioritize sleep and stress management
Important Notes
– Use new sterile syringes for each injection
– At 10.0 mg/mL concentration, all doses through 10 mg/week fit in a single 1 mL syringe
– Rotate injection sites to reduce local irritation
– Document weekly dose, date, and injection site for consistency
– Inject slowly; wait a few seconds before withdrawing needle
Disclaimer
This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before beginning any research protocol.